$XBI $134.31 +0.50%
Covid Updates
$TLSA +5.4% Tiziana Life Sci PLC - P2 Trial with foralumab on Severe COVID19 Patients source
Pipeline Updates
$AZN +0.0% Orpathys approved in China for patients with lung cancer and MET gene alterations source
$KRTX -4.0% Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers source
$VBIV +0.0% Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 source
$CLVS +5.0% Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open For Enrollment source
$GMDA +4.50% Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant source
$EDIT +4.0% Editas Medicine Announces Enrollment Of The First Pediatric Cohort In The BRILLIANCE Clinical Trial Of EDIT-101 For The Treatment Of LCA10 Following IDMC Endorsement source
$CYTK +0.1% Cytokinetics Announces Three Presentations To Occur At The European Society Of Cardiology Heart Failure 2021 Congress source
$ARWR -1.0% Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress source
$JNCE +0.0% Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day source
$LPCN +1.0% Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event source
$ASMB +0.25% Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021 source
$COCP +2.3% Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter source
$PTCT +0.35% Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy source
$SCYX +5.4% SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets) source
$XBIT +1.0% XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer source
$MDNA -6.8% Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 source
$MIRM +1.5% Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021 source
$DRRX -0.6% DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) source
$YMAB +0.6% Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma source
$VALN -0.4% Valneva Announces Successful Outcome of its AGM source
$RUBY +0.2% Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors source
$AGTC +0.7% AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials source
$RCUS +3.0% Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study source
$GNFT -1.0% GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association source
Financial Updates
$LMNL -0.50% Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion source
Posted by JM
Comments